Prevost V, Shuker D E, Friesen M D, Eberle G, Rajewsky M F, Bartsch H
International Agency for Research on Cancer, Unit of Environmental Carcinogens and Host Factors, Lyon, France.
Carcinogenesis. 1993 Feb;14(2):199-204. doi: 10.1093/carcin/14.2.199.
Immunoaffinity gels were prepared by coupling monoclonal antibody (Mab) EM-6-47 to protein A-Sepharose, and were used to make small columns retaining 3-alkyladenines (3-alkAde) of diverse structure. An analytical procedure for determination of 3-methyladenine (3-MeAde), 3-ethyladenine (3-EtAde), 3-(2-hydroxyethyl)adenine (3-HOEtAde) and 3-benzyladenine (3-BzAde) was developed. Deuterated internal standards (d3-3-MeAde, d5-3-EtAde, d4-3-HOEtAde and d7-3-BzAde) were synthesized and added to urine samples prior to immunoaffinity purification. 3-alkAde were separated and quantitated as tert-butyl-dimethylsilyl (TBDMS) derivatives by capillary gas chromatography-low resolution mass spectrometry (GC-MS). Detection limits for 3-MeAde, 3-EtAde and 3-HOEtAde were 0.2 pmol/ml urine and for 3-BzAde, 1 pmol/ml urine. Studies in two volunteers showed that 3-MeAde and 3-HOEtAde were excreted almost quantitatively (> 90%) within 24 h, that 3-EtAde was less well excreted (67-74%) and that 3-BzAde was poorly excreted (21-25%). Studies on basal levels of 3-alkAde urinary excretion in three volunteers showed that 3-MeAde was > 90% derived from the diet as the preformed product. 3-HOEtAde was present at approximately 10 nmol/day and was reduced to approximately 1 nmol/day when the diet was standardized suggesting that it is also dietary in origin. 3-BzAde was not detected in human urine. 3-EtAde was not only excreted at low levels (< 1 nmol/day) but was also only very slightly affected by diet. This general and sensitive method will be useful in biomonitoring studies in subjects exposed to alkylating agents of diverse structure.
通过将单克隆抗体(Mab)EM-6-47偶联到蛋白A-琼脂糖上制备免疫亲和凝胶,并用于制作保留不同结构3-烷基腺嘌呤(3-alkAde)的小柱。建立了一种测定3-甲基腺嘌呤(3-MeAde)、3-乙基腺嘌呤(3-EtAde)、3-(2-羟乙基)腺嘌呤(3-HOEtAde)和3-苄基腺嘌呤(3-BzAde)的分析方法。合成了氘代内标(d3-3-MeAde、d5-3-EtAde、d4-3-HOEtAde和d7-3-BzAde),并在免疫亲和纯化之前添加到尿液样本中。通过毛细管气相色谱-低分辨质谱(GC-MS)将3-alkAde分离并作为叔丁基二甲基硅烷基(TBDMS)衍生物进行定量。3-MeAde、3-EtAde和3-HOEtAde的检测限为0.2 pmol/ml尿液,3-BzAde的检测限为1 pmol/ml尿液。对两名志愿者的研究表明,3-MeAde和3-HOEtAde在24小时内几乎定量排出(>90%),3-EtAde排出较差(67-74%),3-BzAde排出很差(21-25%)。对三名志愿者3-alkAde尿排泄基础水平的研究表明,3-MeAde作为预制产物>90%来自饮食。3-HOEtAde的含量约为10 nmol/天,当饮食标准化时降至约1 nmol/天,表明其也来源于饮食。在人尿中未检测到3-BzAde。3-EtAde不仅排出水平低(<1 nmol/天),而且受饮食影响也非常小。这种通用且灵敏的方法将有助于对接触不同结构烷基化剂的受试者进行生物监测研究。